Previous 10 | Next 10 |
2023-12-14 08:15:55 ET More on Aeterna Zentaris, Ceapro, etc. Seeking Alpha’s Quant Rating on Aeterna Zentaris Historical earnings data for Aeterna Zentaris Financial information for Aeterna Zentaris Financial information for Ceapro For further...
TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“ Ceapro ”), two innovative biopharmaceutical development companies, today announced that they h...
2023-11-09 08:56:55 ET More on Aeterna Zentaris Seeking Alpha’s Quant Rating on Aeterna Zentaris Historical earnings data for Aeterna Zentaris Financial information for Aeterna Zentaris For further details see: Aeterna Zentaris GAAP EPS of -$0.85
- Launch of Ghryvelin ™ in a number of key countries in the European Economic Area - Approval of Macrilen ® in South Korea in September - Ended the quarter with $38.8 million in cash, expected to fund operations and advancement of priority pipeline prog...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Aeterna Zentaris Inc. (AEZS) is expected to report $-0.61 for Q3 2023
– Live moderated webcast with Klaus Paulini, Chief Executive Officer of Aeterna Zentaris on Wednesday, October 25 th at 10:00 AM ET TORONTO, ONTARIO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the &...
TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products,...
2023-08-09 14:48:51 ET Aeterna Zentaris press release ( NASDAQ: AEZS ): Q2 GAAP EPS of -$0.52. Revenue of $2.2M. Total revenue for the three-month period ended June 30, 2023 was $2.2 million as compared with ($0.2 million) for the same period in 2022, representing an i...
News, Short Squeeze, Breakout and More Instantly...
Aeterna Zentaris Inc. Company Name:
AEZS Stock Symbol:
NASDAQ Market:
Aeterna Zentaris Inc. Website:
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for he...
Aeterna Zentaris Inc. (NASDAQ: AEZS) is one of today's top gainers. The company's shares have moved 24.97% on the day to $6.7. Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimore...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.5% to $130.78 on volume of 504,910,586 shares Nikola Corporation (NKLA) fell 31.5% to $0.3296 on volume of 265,124,783 shares SMX (Security Matters) Public Limited Company (SMX) rose 35.1% to $0.1608 o...